Implant may restore sight to the blind

Article

A clinical trial of an electronic subretinal prosthesis has successfully allowed blind patients to recover some perception of single and multiple phosphenes, as well as horizontal and vertical lines.

A clinical trial of an electronic subretinal prosthesis has successfully allowed blind patients to recover some perception of single and multiple phosphenes, as well as horizontal and vertical lines, reported Eberhart Zrenner, MD, at the joint meeting of the European Society of Ophthalmology and American Academy of Ophthalmology.

The device, developed in Germany, consists of a chip with 16 DS electrodes and a subdermally implanted power line, which connects the chip to an external energy supply. One end of the power line is clamped behind the ear and the skin is tunnelled from this point to the upper fornix of the eye. A small scleral flap is created to uncover the choroids and, with the help of a guiding foil, the implant is slid under the retina. A small piece of the retina is preventively detached with a small bleb of fluid, which is eventually removed and replaced with silicone oil.

The prosthesis was implanted for 30 days in seven patients who had had no useful vision for at least five years. All operations were performed without complication. All but one patient was able, in various degrees, to recover perception of single and multiple phosphenes, horizontal and vertical lines and even direction of localized bright objects in dim light. One patient, with the consent of the researchers, has kept the prosthesis in and this may help provide useful, long-term information on biocompatibility.

Further, longer-term studies with an updated version of the implant are currently being planned.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.